Medpace (MEDP) Receiving Somewhat Favorable Press Coverage, Accern Reports

Media coverage about Medpace (NASDAQ:MEDP) has trended somewhat positive on Friday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.373728864858 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Medpace (NASDAQ MEDP) opened at $36.85 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68. Medpace has a 12-month low of $21.76 and a 12-month high of $39.64. The company has a market capitalization of $1,400.65, a P/E ratio of 54.19, a P/E/G ratio of 1.67 and a beta of -1.04.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.04. Medpace had a return on equity of 10.00% and a net margin of 6.44%. The firm had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. During the same period in the previous year, the business earned $0.40 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. analysts predict that Medpace will post 1.5 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. BidaskClub raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Zacks Investment Research raised Medpace from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research note on Wednesday, December 13th. Jefferies Group upped their target price on Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. William Blair downgraded Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Finally, Robert W. Baird upped their target price on Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Medpace currently has a consensus rating of “Hold” and an average target price of $36.60.

In related news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.80% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at

Medpace Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply